Stanley Hirsch
Direktor/Vorstandsmitglied bei MATRICELF LTD
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mutya Harsch | F | 50 |
VYNE Pharmaceuticals Ltd.
 VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 6 Jahre |
| Tal Dvir | M | 49 | 5 Jahre | |
| Alon Sinai | M | 56 | 5 Jahre | |
| Suzana Nahum Zilberberg | F | 53 | 2 Jahre | |
| Ruth Arnon | M | 91 | 3 Jahre | |
| Neomi Enoch | F | 65 | 3 Jahre | |
| Mitchell Shirvan | M | 70 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 10 Jahre |
| Sigal Russo-Gueta | F | 46 | 3 Jahre | |
| Tal Ben Neriah | F | 41 | 4 Jahre | |
| Asaf Toker | M | 51 | 5 Jahre | |
| Doron Pinhas Birger | M | 73 | 4 Jahre | |
| David Schuz | M | 69 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 18 Jahre |
| John Howard Abraham Corre | M | 79 |
FuturaGene Ltd.
 FuturaGene Ltd. BiotechnologyHealth Technology FuturaGene Ltd. researches and develops plant genetic for global biofuel, forestry and agricultural markets. The firm operates on research, development and commercialization of technologies that provide solutions for agriculture in a changing planet. The company is headquartered in London, the United Kingdom. | - |
| Oron Yacoby-Zeevi | M | 63 | 6 Jahre | |
| Doron Cohen | M | 53 | 3 Jahre | |
| Walter Schalka | M | 63 |
FuturaGene Ltd.
FuturaGene Ltd. BiotechnologyHealth Technology FuturaGene Ltd. researches and develops plant genetic for global biofuel, forestry and agricultural markets. The firm operates on research, development and commercialization of technologies that provide solutions for agriculture in a changing planet. The company is headquartered in London, the United Kingdom. | - |
| Tamar Harel Adar | M | 46 | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| David Domzalski | M | 58 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 6 Jahre |
| Ilan Hadar | M | 55 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | - |
| Mordechai Bignitz | M | 72 | 6 Jahre | |
| Meir Eini | M | 69 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 14 Jahre |
| Dov Tamarkin | M | 68 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 15 Jahre |
| Rex Bright | M | 84 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 6 Jahre |
| Daniel Kapi | M | - |
University of Oxford
| 8 Jahre |
| Yannis Stournaras | M | 67 |
University of Oxford
| 3 Jahre |
| Theodore O. Ebel | M | 54 | 6 Jahre | |
| Johann Leitner | M | 70 |
University of Cape Town
| 8 Jahre |
| Noah Walley | M | 61 |
University of Oxford
| 3 Jahre |
| John Denis Newton | M | 74 |
University of Cape Town
| 7 Jahre |
| Michael Hayden | M | 72 |
University of Cape Town
| 8 Jahre |
| William McLendon | M | - |
University of Oxford
| 2 Jahre |
| W. Edward Alastair Morrison | M | 66 |
University of Oxford
| 6 Jahre |
| Andrew Saik | M | 54 | - | |
| Hannah Feuer | F | 69 | 1 Jahre | |
| Yohan Hazot | M | 41 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | - |
| Stephen Julius | M | 65 |
University of Oxford
| 4 Jahre |
| Jackie Sheppard | F | 68 |
University of Oxford
| 5 Jahre |
| Yossi Dagan | M | 48 | 2 Jahre | |
| Anthony Bruno | M | 68 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 2 Jahre |
| Stanley Stern | M | 67 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 6 Jahre |
| Iain Stuart | M | 51 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 4 Jahre |
| Sharon Barbari | F | 70 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | - |
| Darrell S. Rigel | M | 73 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 4 Jahre |
| Anthony Hollis | M | - |
University of Cape Town
| 4 Jahre |
| Paul Berns | M | 57 | 3 Jahre | |
| David McGirr | M | 69 | 3 Jahre | |
| Jonathan Brodie | M | 67 |
University of Cape Town
| 5 Jahre |
| Anna Kazanchyan | M | 55 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 6 Jahre |
| Zvi Riterband | M | 63 | - | |
| Scott Whitcup | M | 64 | 5 Jahre | |
| Matthew Wiley | M | 52 |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | 2 Jahre |
| Matthew le Merle | M | - |
University of Oxford
| 3 Jahre |
| Edward C. Britton | M | - |
University of Oxford
| - |
| Paul A. Smith | M | - |
University of Oxford
| 2 Jahre |
| Richard Andrew Smyth | M | 62 |
University of Oxford
| 4 Jahre |
| Philip Graham New | M | 62 |
University of Oxford
| 1 Jahre |
| Chris Waterhouse | M | - |
University of Oxford
| 5 Jahre |
| Edward Sims | M | 60 |
University of Oxford
| 4 Jahre |
| Heng Heng Goh | M | - |
University of Oxford
| 4 Jahre |
| Peter Lightfoot | M | - |
University of Oxford
| 4 Jahre |
| Richard Kirby Taylor | M | 64 |
University of Oxford
| 4 Jahre |
| Kenneth Bailey | M | 62 |
University of Oxford
| 4 Jahre |
| Jim Mellon | M | - |
University of Oxford
| 3 Jahre |
| Man Sze Li | F | - |
University of Oxford
| 3 Jahre |
| Vaughan Lindsay | M | 62 |
University of Oxford
| 3 Jahre |
| Guan Hong Yap | M | 60 |
University of Oxford
| 4 Jahre |
| Chris Cholerton | M | - |
University of Oxford
| 4 Jahre |
| Vince O’Brien | M | - |
University of Oxford
| 3 Jahre |
| David Morrison | M | 65 |
University of Oxford
| 3 Jahre |
| Reza Abhari | M | 62 |
University of Oxford
| 4 Jahre |
| Donald G. Gilchrist | M | - |
University of Oxford
| 4 Jahre |
| Sarah Elizabeth Street | F | 62 |
University of Oxford
| 3 Jahre |
| Sarah Jane McKay Whitley | F | 65 |
University of Oxford
| 4 Jahre |
| David Fischel | M | 57 |
University of Oxford
| 4 Jahre |
| Helen Weir | F | 62 |
University of Oxford
| 1 Jahre |
| Simon Moroney | M | 65 |
University of Oxford
| 3 Jahre |
| John W. Greenwood | M | - |
University of Oxford
| 4 Jahre |
| Chris Ruffle | M | 65 |
University of Oxford
| 4 Jahre |
| Alastair Tedford | M | 66 |
University of Oxford
| 3 Jahre |
| Soraya Maria Betterton | F | - |
University of Oxford
| 3 Jahre |
| Norman O'Bryan | M | 63 |
University of Oxford
| 3 Jahre |
| John C. Leadley | M | - |
University of Oxford
| 4 Jahre |
| Philippa Aldrich | F | - |
University of Oxford
| 4 Jahre |
| Nigel Binks | M | - |
University of Oxford
| 4 Jahre |
| Fred Cohen | M | 67 |
University of Oxford
| 3 Jahre |
| Eleni D. Dendrinou-Louri | M | 70 |
University of Oxford
| 4 Jahre |
| Patrick N. W. Turner | M | - |
University of Oxford
| 3 Jahre |
| Stephen Swaffield | M | 61 |
University of Oxford
| 4 Jahre |
| Graham Clempson | M | 62 |
University of Oxford
| 3 Jahre |
| Alison Wood | F | 61 |
University of Oxford
| 4 Jahre |
| Jonathan Chenevix-Trench | M | - |
University of Oxford
| 4 Jahre |
| Michele S. Warman | F | - |
University of Oxford
| 4 Jahre |
| Mark Stockdale | M | - |
University of Oxford
| 4 Jahre |
| Ashton Carter | M | 69 |
University of Oxford
| 3 Jahre |
| Marc Tessier-Lavigne | M | 64 |
University of Oxford
| 4 Jahre |
| Nicholas Willson | M | - |
University of Oxford
| 4 Jahre |
| James Mallinson | M | 63 |
University of Oxford
| 3 Jahre |
| Matthew James Whittell | M | - |
University of Oxford
| 4 Jahre |
| Justin Read | M | 63 |
University of Oxford
| 4 Jahre |
| Fabrice Braunrot | M | - |
University of Oxford
| 3 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigtes Königreich | 58 | 58,00% |
| Israel | 32 | 32,00% |
| Vereinigte Staaten | 13 | 13,00% |
| Südafrika | 5 | 5,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Stanley Hirsch
- Persönliches Netzwerk
